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R E V I E W A R T I C L E
START or SMART? Timing of Antiretroviral Therapy
Initiation and Cardiovascular Risk for People With Human
Immunodeﬁciency Virus Infection
Mark J. Siedner
Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston
The Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection (START) study has reinforced the beneﬁts of early
initiation of antiretroviral therapy (ART). However, a notable secondary ﬁnding from that study was that immediate initiation of
ART did not prevent cardiovascular disease (CVD) events (0.17 vs 0.20 events/1000 person-years, P = .65). This result appears to
contradict a body of evidence, most notably from the Strategies for Management of Antiretroviral Therapy (SMART) study, which
reported a 70% increased hazard of cardiovascular events for those deferring or interrupting treatment. Thus, an important unre-
solved question is whether the timing of ART impacts CVD risk. In this review, published data on relationships between timing of
ART and CVD risk are reviewed. The data support a role for ART in mitigating CVD risk at lower CD4 counts, but data also suggests
that, among those initiating therapy early, ART alone appears to suboptimally mitigate CVD risk. Additional interventions to address
CVD risk among human immunodeﬁciency virus-infected populations are likely to be needed.
Keywords. antiretroviral therapy; cardiovascular disease; epidemiology; HIV/AIDS; systematic review.
Two recent landmark studies have lent strong support to a
health beneﬁt of early initiation of antiretroviral therapy
(ART) for asymptomatic human immunodeﬁciency virus
(HIV)-infected patients with high CD4 counts. Both the Trial
of Early Antiretrovirals and Isoniazid Preventive Therapy in
Africa (TEMPRANO) and the Initiation of Antiretroviral Ther-
apy in Early Asymptomatic HIV Infection (START) studies
reported reductions of over 40% in the risk of death or an ac-
quired immune deﬁciency syndrome (AIDS)-deﬁning event
when ART was initiated immediately instead of waiting until
CD4 thresholds were met (<350 cells/µL in the START study,
or the contemporary World Health Organization-based guide-
lines in the TEMPRANO study) [1,2]. Both studies demonstrated
decreased risk of opportunistic infections and appreciable, albeit
nonsigniﬁcant, reductions in all-cause mortality. However, an
unexpected result from the START study was the rate of cardio-
vascular disease (CVD) events, which did not differ between im-
mediate initiators and those deferring therapy (adjusted hazard
ratio, 0.84; 95% conﬁdence interval [CI], .39–1.81; P = .65). The
TEMPRANO study, which was not designed to capture cardio-
vascular events, did not report a similar subanalysis.
The ﬁnding that early ART for asymptomatic HIV-infected
individuals did not prevent CVD complications seems to con-
tradict a body of evidence relating HIV infection to CVD risk.
Most notably, a landmark study comparing CD4-count-guided
treatment interruptions with continuous ART (Strategies for
Management of Antiretroviral Therapy [SMART] study) dem-
onstrated an approximate 70% increase in CVD events in those
taking treatment interruptions. Resolving the beneﬁt of ART
timing and its impact on CVD risk is a critical question for
the ﬁeld of clinical HIV care. If the beneﬁts are signiﬁcant,
then prioritizing early diagnosis and linkage to ART might pro-
vide signiﬁcant CVD health beneﬁts. If the beneﬁts are not sig-
niﬁcant, then the search for alternate interventions in addition
to ART to mitigate CVD risk in this population will be crucial.
This review aims to summarize the evidence about relationships
between timing of ART initiation and CVD risk, using nadir
CD4 count as a surrogate marker of duration of HIV infection,
and with a particular focus on the impact of early ART on pre-
vention of CVD events.
THE SMART STUDY, TREATMENT INTERRUPTIONS,
AND CARDIOVASCULAR DISEASE RISK
Soon after it was discovered that combination ART profoundly
improved survival for patients with AIDS [3, 4], it became
evident that HIV-infected patients were at higher risk than
the general population of non-AIDS-related conditions [5–8].
Cardiovascular disease, and particularly myocardial infarction
and stroke, were among the greatest non-AIDS risks, and
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ART rather than HIV infection was thought to be the primary
culprit [5, 9, 10]. Concerns about avoiding the toxicity of chron-
ic ART in part spurred a change in the US HIV treatment guide-
lines to downgrade recommendations to initiate ART for those
with a CD4 of 200–350 from “recommended” to “optional”
during the period 2001–2006 [11]; and a large randomized con-
trolled trial was conducted to evaluate whether discontinuing
ART decreased non-AIDS-related HIV complications. The
SMART study randomized approximately 5000 patients infect-
ed with HIV on stable ART with a CD4 count above 350 to con-
tinuing ART, versus mandated treatment interruptions until
CD4 counts dropped below 250, at which point ART was
reinitiated [12].
Arguably the most informative result to come from the
SMART study was not that treatment interruptions increased
the risk of opportunistic infections or mortality, but that pa-
tients taking interruptions from ART had an approximately
70% increased risk of cardiovascular complications; moreover,
major cardiovascular events occurred 5 times more often than
opportunistic infections in those with treatment interruptions
(Table 1). The SMART study suggested that, whereas speciﬁc
ART drugs or drug classes might be associated with a relative
CVD risk versus others [13, 14], CVD risk is largely mediated
by the effects of untreated HIV infection.
Although the primary SMART study analysis did not differ-
entiate between ART interruptions and timing of ART initia-
tion, in a subsequent analysis, the investigators speciﬁcally
considered a clinical beneﬁt of earlier ART initiation. When
limiting their analysis to the 488 study participants who were
ART naive or off therapy for a minimum of 6 months before
study enrollment, investigators found a 7 times increased haz-
ard of a cardiovascular event or non-AIDS illness in those ini-
tiating therapy at <250 vs >350 cells/µL [15]. As the only study
randomizing patients to early versus deferred ART initiation
with measured CVD outcomes at the time, this study subanal-
ysis offered the strongest clinical evidence for a preventive role
for earlier ART initiation.
Since then, an elegant body of basic and translational research
has provided a strong pathophysiologic rationale for a causative
role for HIV infection on CVD risk [16]. A combination of im-
mune activation due to HIV and coinfections [17–19],direct HIV
infection of vasculature smooth muscle [20, 21], and profound
and irreversible depletion of gut T-lymphocytes with resulting
microbial translocation [22–24] are thought to combine to pre-
cipitate a chronic inﬂammatory state. Reactive T-lymphocytes
and macrophages [25, 26] have been correlated with both CVD
outcomes and all-cause mortality [27–30]. Indeed, recent data
suggest that as mortality for HIV-infected individuals has de-
creased from AIDS-deﬁning illnesses, CVD has become the sec-
ond most common cause of death, after cancer, among those
with an undetectable viral load [31]. However, although basic sci-
ence supports the role of HIV-mediated inﬂammation as a caus-
ative agent in CVD risk, clinical data are crucial to translating this
theory into improvements for patient care.
ANTIRETROVIRAL THERAPY TIMING AND
PRECLINICAL ATHEROSCLEROSIS
A host of nonrandomized studies have investigated the relation-
ship between nadir CD4 count and risk of preclinical atheroscle-
rosis, without convincing evidence for a relationship between
disease stage at ART initiation and CVD risk (Table 2). It is no-
table that although multiple studies have reported a relationship
between HIV infection itself and carotid intima media thickness
(cIMT) [55], only 1 has demonstrated an inverse relationship be-
tween nadir CD4 count and cIMT (such that a lower nadir CD4
count is associated with a greater mean cIMT) [32]. In addition,
although Hsue et al [43] reported a relationship between lower
CD4 count and cIMT progression over time (Table 2), a large
prospective study of over 1000 individuals infected with HIV
has since reported a counterintuitive direct relationship (such
that higher nadir CD4 count was associated with increased pro-
gression) [46]. These differential estimates might partially be
explained by cohort characteristics. For example, patients in
the Hsue et al [43] study had relatively low median nadir CD4
(approximately 200 vs 500 cells/µL), contained a higher propor-
tion of males, and were more likely to be current smokers and
have hypertension.
Although less commonly evaluated than cIMT, the presence
of carotid plaques has been better associated with nadir CD4
count (Table 2). Investigators of the Multi-Centre AIDS Cohort
Study and Women’s Interagency Health Study (MACS/WIHS)
have reported greater carotid plaque volume with decreasing
nadir CD4 count [33, 46]. This causal relationship is strength-
ened by the presence of a dose-response relationship correlating
lower nadir CD4 count with increased prevalence and incidence
of carotid plaque.
More recently, several studies have reported strong associa-
tions between HIV infection and presence of preclinical coro-
nary artery disease and aortic wall inﬂammation (Table 2).
The largest of these, also from the MACS/WIHS collaboration,
reported a 20% decreased odds of coronary stenosis (>50%) for
each increase in nadir CD4 count of 100 cells/µL [53].However,
similar to carotid atherosclerosis, the majority of similar studies
have not found signiﬁcant relationships between nadir CD4
count and preclinical disease (Table 2). It is notable that
Table 1. Outcomes Reported in the SMART Study [12]
Outcome Relative Risk for Treatment Interruption Total Events
Death 1.8 (1.2–2.9) 85
Serious OI 6.6 (1.5–29) 15
Major CV Event 1.7 (1.1–2.5) 104
Abbreviations: CV,cardiovascular; OI,opportunistic infection; SMART,Strategies for
Management of Antiretroviral Therapy.
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Table 2. Summary of Studies Reporting Relationships Between Nadir CD4 Count and Preclinical Atherosclerosis
Study Year Study Design
HIV-Infected
Sample Size
Cohort Median
Nadir CD4 Count
Relationship Between
CD4 Nadir and
Atherosclerosis Risk Main Findings
Current Carotid Intima Media Thickness
Jerico et al
[32]
2006 Cross-Sectional 132 250 Inverse Increased odds of cIMT >0.8 mm with a nadir CD4
count <200 vs ≥200 cells/µL (OR, 2.9; 95% CI, 1.4–
5.9)
Kaplan et al
[33]
2008 Cross-sectional 1931 ∼450a None No association between nadir CD4 count and mean
cIMT in men (estimate not reported)
Ross et al [34] 2009 Cross-sectional 73 161 (0–868) None No association between nadir CD4 count and cIMT
(β < 0.01, P = .88)
van Vonderen
et al [35]
2009 Cross-sectional 77 ∼184a None No association between cIMT and nadir CD4 count
(estimate not reported)
Merlini et al
[36]
2012 Cross-sectional 163 210 (99–326) None No difference in nadir CD4 count between those with
normal cIMT (≤1 cm), those with increased cIMT
(1.0–1.5 cm), and those with carotid plaque (cIMT
> 1.5 cm), (P = .74)
Longenecker
et al [37]
2013 Cross-sectional 78 NR None No association between nadir CD4 count and mean
cIMT (P = .80)
Desvarieux
et al [38]
2013 Cross-sectional 100 ∼345a None No difference in adjusted mean cIMT between ART-
naive and on ART (4 y) participants Increase in
adjusted mean cIMT between those with HIV more
than vs <8 years (0.760 vs 0.731, P = .02)
Ssinabulya
et al [39]
2014 Cross-sectional 245 124 (42–195) None No difference in nadir CD4 count between those with
elevated cIMT (≥0.78) and those with normal cIMT
Boyd et al [40] 2014 Cross-sectional 47 ∼222a None Nonsignificant association between cIMT and nadir
CD4 count (β =−0.001, P = .9)
Siedner et al
[41]
2015 Cross-sectional 105 122 (80–175) Direct Increase mean cIMT with each increase in nadir CD4
count of 50 cells/µL (0.014 mm, P = .02)
Pacheco et al
[42]
2015 Cross-sectional 591 213 (90–314) None Mean nadir CD4 count 215 in lowest tertile of cIMT vs
178 in highest tertile of cIMT (P = .054)
Progression of Carotid Intima Media Thickness
Hsue et al [43] 2004 Prospective
cohort
148 106 Inverse Increased rate of progression of cIMT for participants
with a nadir CD4 < 200 (0.0043 mm/year, P = .08)
Currier et al
[44]
2007 Prospective
cohort
134 NR (∼35% with
nadir
CD4 < 200)
Direct Decreased odds of rapid progression of cIMT (defined
as 1 SD, ie, 0.0122 mm/year) for participants with a
nadir CD4 count <200 (AOR, 0.10; P = .04)
Volpe et al [45] 2013 Prospective
Cohort
345 161 (70–276) Direct Decreased rate of cIMT progression for each decrease
in 100 cells/µL nadir CD4 count (−0.005 mm/year;
SD, 0.002)
Hanna et al
[46]
2015 Prospective
Cohort
1277 ∼483a None No association between CD4 nadir and progression of
cIMT thickness (RR compared <200 cells vs >500
cells/µL 1.13, 95% CI, .56–2.29, P = .73).
Stein [47] 2015 Randomized
clinical trial
328 349 (203–455) None No association between pretreatment CD4% and
cIMT progression (β =−0.07, P = .28)
Current Carotid Artery Plaque
Kaplan et al
[33]
2008 Cross-sectional 1931 ∼450a Inverse Increased adjusted risk of carotid plaque with lower
nadir CD4 count (vs HIV-uninfected as reference
group):
CD4 nadir > 500: RR 0.88 (women), 1.24 (men),
P > .18
CD4 nadir <200: RR 2.00 (women), 1.74 (men), P ≤ .05
Incident Carotid Plaque
Hanna [46] 2015 Prospective
Cohort
1277 ∼483a Inverse Increased adjusted risk of incident carotid plaque with
lower nadir CD4 count (vs HIV-uninfected as
reference group):
CD4 nadir >500: RR 1.28, 0.85–1.94, P = .23
CD4 nadir 350–500: RR 1.65, 1.03–2.64, P = .039
CD4 nadir 300–350: RR 1.96, 1.20–3.21, P = .007
CD4 nadir <200: RR 2.57, 1.48–4.46, P < .001
Aortic Wall Inflammation (FDG PET)
Subramanian
et al [48]
2012 Cross-sectional 27 99 (50–250) None No correlation between nadir CD4 count and aortic
wall inflammation
Preclinical Coronary Artery Disease
Lo et al [49] 2010 Cross-sectional 78 169 (54–263) None No correlation between nadir CD4 count and segment
of plaque (P = .49), plaque volume (P = .66), or
Agatston calcium score (P = .83)
ART Timing and CVD Risk • OFID • 3
many of these studies are potentially unpowered to detect asso-
ciations between nadir CD4 and CVD risk. Nonetheless, a
meta-analysis of studies including data from approximately
1000 individuals infected with HIV found no signiﬁcant associ-
ation between nadir CD4 count and either noncalciﬁed plaque
(P = .45) or coronary artery stenosis (P = .87) [56].
ANTIRETROVIRAL THERAPY TIMING AND
CARDIOVASCULAR DISEASE OUTCOMES IN
COHORT STUDIES
Several large data sets in the United States, including the Veter-
an’s Aging Cohort Study (VACS), Partners Healthcare and the
Kaiser Permanente Healthcare system, as well as large or na-
tional cohorts from France and Denmark, have enabled estima-
tion of HIV-related CVD risk (Table 3). In general, these cohort
studies increase the support for associations between nadir CD4
count and CVD risk. For example, in the Kaiser cohort, CVD
incidence declined over calendar time (1999–2011) as popula-
tion nadir CD4 increased. At the conclusion of their observa-
tion period (2010–2011), they found no difference in risk of
myocardial infarction between HIV-infected and uninfected
populations (relative risk [RR], 1.0; 95% CI, .7–1.4). The au-
thors [67] point out that their data might be confounded by
the fact that the proportion of patients receiving therapy for
CVD-related conditions also increased during the period. How-
ever, if their estimates are unbiased, these data would support
ﬁndings from the START study, which demonstrates normali-
zation of CVD risk, compared with the general population, as
nadir CD4 counts increased. A second study from the Kaiser
investigators, which included more than 22 000 individuals
infected with HIV, speciﬁcally assessed relationships between
nadir CD4 and CVD risk and demonstrated a decreased risk
of myocardial infarction with each 100 cell/µL increase in
nadir CD4 count [61]. A case-control study from France noted
a similar relationship [59].Moreover, although the Partners co-
hort investigators, the VACS study investigators, and the HIV
Outpatient Study investigators demonstrated relationships be-
tween most recent CD4 count and risk of incidence myocardial
infarction, they did not assess nadir CD4 count in their reports
[28, 60], or they found no association between nadir CD4 and
CVD events [58]. Finally, of 5 studies that have explored rela-
tionships between HIV disease stage and stroke risk, only 1
identiﬁed an inverse relationship between CD4 nadir and stroke
risk (Table 3), reporting that a nadir CD4 count below 200 cells/
µL more than doubled the risk of stroke [62].
ANITRETROVIRAL THERAPY TIMING AND
CARDIOVASCULAR DISEASE OUTCOMES IN
RANDOMIZED CLINICAL TRIALS: SMART VERSUS
START
Although the above body of evidence suggests a possible, if not
inconsistent, role for early ART initiation in mitigating CVD
risk, these data have a number of important limitations. First,
many of the studies are limited to relatively small sample
sizes, preventing the ability to detect small contributions of
ART timing to CVD risk. Second, most cohort studies are ho-
mogenous in important ways, including restricting to gender
(eg, VACS and MACS cohorts), and, more importantly, to
small distributions in nadir CD4 count, which limits the ability
to compare those initiating early ART with those initiating late
Table 2 continued.
Study Year Study Design
HIV-Infected
Sample Size
Cohort Median
Nadir CD4 Count
Relationship Between
CD4 Nadir and
Atherosclerosis Risk Main Findings
Burdo [25] 2011 Cross-sectional 102 202 None No correlation between nadir CD4 count and
noncalcified coronary artery plaque (estimate not
reported)
Duarte et al
[50]
2012 Cross-sectional 26 269 None Borderline, nonsignificant increase in noncalcified
plaque volume with decreasing nadir CD4 count
(r =−0.36, P = .07)
Pereyra [51] 2012 Cross-sectional 113 221a None Nonsignificant increased prevalence of plaque on CT
coronary angiogram among elite controllers with
high nadir CD4 than chronic HIV cohort (78% vs
60%, P = .28)
Zanni [52] 2013 Cross-sectional 102 175 (57–278) None No correlation between nadir CD4 count and number
of low attenuation coronary artery plaques (P = .72)
Post [53] 2014 Cross-sectional 618 244 (133–332) Inverse Decreased risk of coronary artery stenosis >50% for
each 100 cell/µL increase in nadir CD4 count (AOR
0.80, 0.69–0.94, P = .005).
Abd-
Elmoniem
[54]
2014 Cross-sectional 35 202 None No association between nadir CD4 count and right
coronary artery atherosclerosis as measured by CT
angiography (no estimate reported)
Abbreviations: AOR, adjusted odds ratio; ART,antiretroviral therapy; CI, confidence interval;cIMT, carotid intima media thickness; CT,computed tomography;FDG-PET, fluorodeoxyglucose-
positron emission tomography; HIV, human immunodeficiency virus; NR, not reported; OR, odds ratio; RR, relative risk; SD, standard deviation.
a Median nadir CD4 count approximated from weighted average of subgroups.
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ART. Third, and most important, cohort studies are challenged
by residual or unmeasured confounding, such that unaccounted
factors associated with both nadir CD4 count and CVD risk (eg,
access to high-quality primary care services) could alter estimates
of the relationship between them. To overcome these limitations,
randomization to early or deferred therapy is needed to better
estimate relationships between timing of ART and CVD risk.
Both the SMART and START studies addressed this need
through randomization of HIV-infected persons to ART or
either ART discontinuation (SMART) or deferring ART initia-
tion (START), respectively. As summarized above, the SMART
study reported a 70% increased risk of cardiovascular complica-
tions for discontinuing therapy, whereas the START study
found no increased risk of cardiovascular complications when
initiating ART was deferred.
How can we explain the differences between these 2 studies?
It is possible that treatment interruptions (as in SMART) have
differential effects on CVD risk than delayed therapy among
ART-naive individuals (as in START). However, as mentioned
above, the SMART investigators identiﬁed similar relationships
in a substudy limited to those initiating ART [15]. There are
other important differences between the 2 study populations,
which theoretically could explain differences in relative rates
of CVD events. For example, approximately 50% of patients
in the SMART study were on a protease inhibitor, compared
with only 20% of patients in the START study, and approxi-
mately 6% vs 4% were prescribed abacavir, respectively. Al-
though the regimen imbalance might partially explain the
relative increased overall risk of CVD events witnessed in the
SMART study, it does not explain the difference in risk compar-
ing those on ART with those who are not. In fact, the relation-
ship observed was counterintuitive, because the regimens in use
in the SMART study were more likely to be associated with met-
abolic abnormalities and would thus be predicted to have a rel-
atively decreased effect on CVD prevention than the regimens
used in the START study. Other key differences between study
Table 3. Summary of Studies Reporting Relationships Between Nadir CD4 Count and Cardiovascular Disease Events
Study Year Study Design
HIV-Infected
Sample Size
Cohort Median
Nadir CD4
Count
Relationship Between
CD4 Nadir and
Atherosclerosis Risk Main Findings
Myocardial Infarction
Obel et al [57] 2007 Retrospective
Cohort
3953 182 (74–290) None or inverse Absolute increase in risk of myocardial infarction for
those with nadir CD4 count ≤200 cells/µL (RR 2.28,
95% CI, 1.63–3.19) vs those with a nadir CD4 count
>200 cells/µL (RR 1.80, 95% CI, 1.17–2.78). No
interaction term reported.
Friis-Møller
et al [5]
2007 Prospective
Cohort
23 437 200 (range 1–
2580)
None No association between nadir CD4 count and risk of
myocardial infarction (0.98, 95% CI, .95–1.01) for
each 50 cells/µL increase
Lichtenstein
et al [58]
2010 Retrospective
Cohort
2005 197 None No association between nadir CD4 count and
subsequent cardiovascular event (OR 1.34, 95% CI,
.64–2.83 for nadir CD4 <350 vs >500)
Lang et al [59] 2012 Case Control 1173 167a Inverse Increase in risk of myocardial infarction with each log2
decrease in nadir CD4 count (OR 0.90, 95% CI,
.83–.97)
Freiberg et al
[60]
2013 Retrospective
Cohort
27 350 362 None No association between baseline CD4 (first record in
veterans affairs system) and incident myocardial
infarction (no estimate reported)
Silverberg
et al [61]
2015 Retrospective
Cohort
22 081 Not reported Inverse Decrease in risk of myocardial infarction with each 100-
cell increase in nadir CD4 account (ARR 0.88, 95% CI
.81–.96).
Stroke
Rasmussen
et al [62]
2011 Retrospective
Cohort
4495 292a Inverse Increase in risk of stroke among those not on ARTwith a
nadir CD4 count ≤200 vs >200 cell/µL (ARR 2.26,
95% CI, 1.05–4.86).
Chow et al
[63]
2012 Retrospective
Cohort
4308 271 None No association between nadir CD4 count and risk of
stroke (0.97, 95% CI, .90–1.05 for each 50 cells/µL).
Vinikoor et al
[64]
2013 Retrospective
Cohort
2515 235 (69–407) None No association between risk of ischemic stroke and
nadir CD4 count ≤200 vs >200 cells/µL (RR 1.31,
95% CI, .76–2.26) for nadir CD4 count
Marcus et al
[65]
2014 Retrospective
Cohort
24 768 Not reported None Among the HIV+ group, no association between nadir
CD4 count and risk of stroke (RR 0.80, 95% CI, .4–1.6
comparing nadir CD4<200 with ≥500).
Chow et al
[66]
2014 Case Control 60 73 None No association between nadir CD4 count and odds of
ischemic stroke (OR 1.05, 95% CI, .81–1.36 per each
100 cells/µL)
Abbreviations: ARR, adjusted relative risk; ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio; RR, relative risk.
a Median nadir CD4 count approximated from weighted average of subgroups.
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groups include a higher median age in the SMART study (43 vs
36 years) and slightly higher rates of current smoking (40% vs
32%), but it is unlikely that these relatively modest differences
would account for the approximately 7-fold increased risk of
CVD events noted in the SMART study.
Another key difference between study groups was the nadir
CD4 count. At enrollment, study participants in the START
study had a median nadir CD4 count of 651 cells/µL and a
known HIV duration of only 1 year. Moreover, mean CD4
count in the deferred therapy never dropped below 600 cells/
µL. In contrast, the median nadir CD4 in the SMART study
was 250 cells/µL, and over half of participants had over 6
years of HIV infection before enrollment. Those in the drug
conservation group spent most of the observation time (73%)
with detectable viral loads and with CD4 counts <500 cells/
µL. As such, even the deferred therapy group in the START
study can be considered to have signiﬁcantly shorter duration
of HIV viremia and duration of time with low CD4 counts com-
pared with those in the SMART continued therapy arm.
An examination of these 2 studies in combination reveals a
nonlinear relationship between nadir CD4 count and CVD
risk (Table 4), and the results of this review challenges the im-
plication supported by the START study, which, taken in isola-
tion, suggests that early ART does not prevent CVD outcomes.
Instead, early and continuous ART for those with advanced dis-
ease does appear to be protective against CVD events. However,
for those starting ART relatively early (>500 cells/µL), CVD risk
is not clearly reduced substantially by the timing of ART initi-
ation. In other words, above some unclear threshold of immune
depletion, earlier ART initiation seems to have a diminished
role in preventing CVD risk. It is unlikely that future studies
will further elucidate this threshold due to the overwhelming ev-
idence in support of early ART described by the START and
TEMPRANO studies. As such, for those starting therapy with
preserved immune function, further reductions in risk will like-
ly require additional, non-ART-based interventions.
CONCLUSIONS
In summary, the published literature on the timing of ART ini-
tiation and CVD risk supports 3 primary conclusions. First,
data from the SMART study, in combination with a handful
of nonrandomized studies noting relationships between lower
nadir CD4 and increased risk of preclinical or clinical CVD
[32, 43, 53, 59, 61, 62], suggest that earlier initiation of ART
has a protective effect against CVD events. The majority of
these studies, including the SMART study, involved those
with relatively low nadir CD4 counts (<250 cells/µL), which
lends the strongest support for the beneﬁt of ART among
those with advanced disease. Notwithstanding recent recom-
mendations to initiate ART independent of immune status,
this implication remains of importance for much of the world’s
HIV-infected population, because most patients continue to
initiate ART well below recommended guidelines [68–70].
Second, a recent group of large cohort studies demonstrate
associations between a low recent CD4 count (as opposed to
nadir CD4 count) and/or current detectable HIV-1 viremia
and clinical outcomes [28, 58, 60]. In combination with results
of the SMART study, these data support a role for continuous
ART among those who have initiated therapy, to prevent
HIV-associated chronic inﬂammation and resulting CVD risk.
Third, for patients starting ART above a CD4 count threshold of
500 cells/µL, the START study suggests that earlier ART initia-
tion has marginal beneﬁts in terms of mitigating CVD risk.
This realization should foster further consideration of non-
ART interventions to decrease CVD risk among HIV-infected
populations initiating therapy with preserved immune function
[71, 72].
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